APA (7th ed.) Citation

Hansen, C. R., Bertelsen, A. S., Hazell, I., Stougaard, S. W., Johansen, J., Overgaard, J., . . . Zukauskaite, R. (2025). Eliminating the high-risk CTV1 margin in DAHANCA oropharyngeal radiotherapy: Dosimetric impact on dysphagia and organ-at-risk doses. Acta Oncologica, 64, 1205. https://doi.org/10.2340/1651-226X.2025.44049

Chicago Style (17th ed.) Citation

Hansen, Christian Rønn, Anders S. Bertelsen, Irene Hazell, Sarah W. Stougaard, Jørgen Johansen, Jens Overgaard, Jesper Grau Eriksen, and Ruta Zukauskaite. "Eliminating the High-risk CTV1 Margin in DAHANCA Oropharyngeal Radiotherapy: Dosimetric Impact on Dysphagia and Organ-at-risk Doses." Acta Oncologica 64 (2025): 1205. https://doi.org/10.2340/1651-226X.2025.44049.

MLA (9th ed.) Citation

Hansen, Christian Rønn, et al. "Eliminating the High-risk CTV1 Margin in DAHANCA Oropharyngeal Radiotherapy: Dosimetric Impact on Dysphagia and Organ-at-risk Doses." Acta Oncologica, vol. 64, 2025, p. 1205, https://doi.org/10.2340/1651-226X.2025.44049.